In this special video episode of Not So Different, co-hosts Giuseppe Randazzo and Alex Keeton from the Association of ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in ...
New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced ...
FDA approves Poherdy, the first interchangeable biosimilar for pertuzumab (Perjeta), enhancing competition in HER2-positive ...
Patients with Crohn disease report high satisfaction and minimal discomfort using the citrate-free biosimilar CT-P17, enhancing adherence to treatment.
April E. Weisbruch is a partner at McDermott, Will, & Emery LLP. She focuses her practice on intellectual property (IP) matters, particularly in managing large-scale IP litigation and counseling. She ...
After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback